137 related articles for article (PubMed ID: 34593531)
1. TAS-116 (Pimitespib), an Oral HSP90 Inhibitor, in Combination with Nivolumab in Patients with Colorectal Cancer and Other Solid Tumors: An Open-Label, Dose-Finding, and Expansion Phase Ib Trial (EPOC1704).
Kawazoe A; Itahashi K; Yamamoto N; Kotani D; Kuboki Y; Taniguchi H; Harano K; Naito Y; Suzuki M; Fukutani M; Higuchi T; Ikeno T; Wakabayashi M; Sato A; Koyama S; Nishikawa H; Shitara K
Clin Cancer Res; 2021 Dec; 27(24):6709-6715. PubMed ID: 34593531
[TBL] [Abstract][Full Text] [Related]
2. Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603).
Fukuoka S; Hara H; Takahashi N; Kojima T; Kawazoe A; Asayama M; Yoshii T; Kotani D; Tamura H; Mikamoto Y; Hirano N; Wakabayashi M; Nomura S; Sato A; Kuwata T; Togashi Y; Nishikawa H; Shitara K
J Clin Oncol; 2020 Jun; 38(18):2053-2061. PubMed ID: 32343640
[TBL] [Abstract][Full Text] [Related]
3. Nivolumab plus ONC201 plus in microsatellite stable (MSS) metastatic colorectal cancer (mCRC) patients: a Brown University Oncology Research Group phase Ib/II study (BrUOG379).
Almhanna K; Breakstone R; Raufi A; Wood R; Webber A; Dionson S; Cavanagh L; Seyhan AA; Safran H; El-Deiry W
Transl Gastroenterol Hepatol; 2024; 9():15. PubMed ID: 38716219
[TBL] [Abstract][Full Text] [Related]
4. Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical Trial.
Heinhuis KM; Carlino M; Joerger M; Di Nicola M; Meniawy T; Rottey S; Moreno V; Gazzah A; Delord JP; Paz-Ares L; Britschgi C; Schilder RJ; O'Byrne K; Curigliano G; Romano E; Patah P; Wang R; Liu Y; Bajaj G; Siu LL
JAMA Oncol; 2020 Jan; 6(1):100-107. PubMed ID: 31697308
[TBL] [Abstract][Full Text] [Related]
5. VB-111 (ofranergene obadenovec) in combination with nivolumab in patients with microsatellite stable colorectal liver metastases: a single center, single arm, phase II trial.
Coffman-D'Annibale K; Myojin Y; Monge C; Xie C; Hrones DM; Wood BJ; Levy EB; Kleiner D; Figg WD; Steinberg SM; Redd B; Greten TF
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38184304
[TBL] [Abstract][Full Text] [Related]
6. Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study.
Elez E; Cubillo A; Alfonso PG; Middleton MR; Chau I; Alkuzweny B; Alcasid A; Zhang X; Van Cutsem E
BMC Cancer; 2024 Apr; 24(1):446. PubMed ID: 38600471
[TBL] [Abstract][Full Text] [Related]
7. A phase 2 trial of trifluridine/tipiracil plus nivolumab in patients with heavily pretreated microsatellite-stable metastatic colorectal cancer.
Patel MR; Falchook GS; Hamada K; Makris L; Bendell JC
Cancer Med; 2021 Feb; 10(4):1183-1190. PubMed ID: 33544407
[TBL] [Abstract][Full Text] [Related]
8. First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors.
Shimomura A; Yamamoto N; Kondo S; Fujiwara Y; Suzuki S; Yanagitani N; Horiike A; Kitazono S; Ohyanagi F; Doi T; Kuboki Y; Kawazoe A; Shitara K; Ohno I; Banerji U; Sundar R; Ohkubo S; Calleja EM; Nishio M
Mol Cancer Ther; 2019 Mar; 18(3):531-540. PubMed ID: 30679388
[TBL] [Abstract][Full Text] [Related]
9. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
[TBL] [Abstract][Full Text] [Related]
10. Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated - NIVACOR trial (GOIRC-03-2018).
Damato A; Iachetta F; Antonuzzo L; Nasti G; Bergamo F; Bordonaro R; Maiello E; Zaniboni A; Tonini G; Romagnani A; Berselli A; Normanno N; Pinto C
BMC Cancer; 2020 Aug; 20(1):822. PubMed ID: 32867715
[TBL] [Abstract][Full Text] [Related]
11. ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial.
Wrangle JM; Velcheti V; Patel MR; Garrett-Mayer E; Hill EG; Ravenel JG; Miller JS; Farhad M; Anderton K; Lindsey K; Taffaro-Neskey M; Sherman C; Suriano S; Swiderska-Syn M; Sion A; Harris J; Edwards AR; Rytlewski JA; Sanders CM; Yusko EC; Robinson MD; Krieg C; Redmond WL; Egan JO; Rhode PR; Jeng EK; Rock AD; Wong HC; Rubinstein MP
Lancet Oncol; 2018 May; 19(5):694-704. PubMed ID: 29628312
[TBL] [Abstract][Full Text] [Related]
12. Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors.
Lemech C; Dredge K; Bampton D; Hammond E; Clouston A; Waterhouse NJ; Stanley AC; Leveque-El Mouttie L; Chojnowski GM; Haydon A; Pavlakis N; Burge M; Brown MP; Goldstein D
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36634920
[TBL] [Abstract][Full Text] [Related]
13. Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study.
Awad MM; Le Bruchec Y; Lu B; Ye J; Miller J; Lizotte PH; Cavanaugh ME; Rode AJ; Dumitru CD; Spira A
Front Oncol; 2021; 11():696512. PubMed ID: 34552864
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of nivolumab and metformin in patients with treatment-refractory microsatellite stable metastatic colorectal cancer.
Akce M; Farran B; Switchenko JM; Rupji M; Kang S; Khalil L; Ruggieri-Joyce A; Olson B; Shaib WL; Wu C; Alese OB; Diab M; Lesinski GB; El-Rayes BF
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37852737
[TBL] [Abstract][Full Text] [Related]
15. Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial.
Naing A; Wong DJ; Infante JR; Korn WM; Aljumaily R; Papadopoulos KP; Autio KA; Pant S; Bauer TM; Drakaki A; Daver NG; Hung A; Ratti N; McCauley S; Van Vlasselaer P; Verma R; Ferry D; Oft M; Diab A; Garon EB; Tannir NM
Lancet Oncol; 2019 Nov; 20(11):1544-1555. PubMed ID: 31563517
[TBL] [Abstract][Full Text] [Related]
16. Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with immune checkpoint inhibitors in patients with advanced solid tumors.
Bagegni NA; Park H; Kraft K; O-Toole M; Gao F; Waqar SN; Ratner L; Morgensztern D; Devarakonda S; Amin M; Baggstrom MQ; Liang C; Selvaggi G; Wang-Gillam A
Cancer Chemother Pharmacol; 2022 Apr; 89(4):487-497. PubMed ID: 35247086
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations.
Nishio M; Murakami H; Ohe Y; Hida T; Sakai H; Kasahara K; Imamura F; Baba T; Kubota K; Hosomi Y; Shimokawa T; Hayashi H; Miyadera K; Tamura T
Invest New Drugs; 2019 Dec; 37(6):1207-1217. PubMed ID: 30790152
[TBL] [Abstract][Full Text] [Related]
18. Study Protocol: Phase-Ib Trial of Nivolumab Combined With Metformin for Refractory/Recurrent Solid Tumors.
Kubo T; Ninomiya T; Hotta K; Kozuki T; Toyooka S; Okada H; Fujiwara T; Udono H; Kiura K
Clin Lung Cancer; 2018 Nov; 19(6):e861-e864. PubMed ID: 30172698
[TBL] [Abstract][Full Text] [Related]
19. CXD101 and nivolumab in patients with metastatic microsatellite-stable colorectal cancer (CAROSELL): a multicentre, open-label, single-arm, phase II trial.
Saunders MP; Graham J; Cunningham D; Plummer R; Church D; Kerr R; Cook S; Zheng S; La Thangue N; Kerr D
ESMO Open; 2022 Dec; 7(6):100594. PubMed ID: 36327756
[TBL] [Abstract][Full Text] [Related]
20. Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer.
Morse MA; Overman MJ; Hartman L; Khoukaz T; Brutcher E; Lenz HJ; Atasoy A; Shangguan T; Zhao H; El-Rayes B
Oncologist; 2019 Nov; 24(11):1453-1461. PubMed ID: 31147488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
